65 related articles for article (PubMed ID: 24324114)
1. Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
Panebianco V; Iacovelli R; Barchetti F; Altavilla A; Forte V; Sciarra A; Cortesi E; Catalano C
Anticancer Res; 2013 Dec; 33(12):5663-6. PubMed ID: 24324114
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
Rosen MA; Schnall MD
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
4. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
5. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
[TBL] [Abstract][Full Text] [Related]
8. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma.
Busch J; Seidel C; Goranova I; Erber B; Peters R; Friedersdorff F; Magheli A; Miller K; Grünwald V; Weikert S
Eur J Cancer; 2014 Feb; 50(3):563-9. PubMed ID: 24239449
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.
Grassi P; Verzoni E; Porcu L; Testa I; Iacovelli R; Torri V; Braud Fd; Procopio G
Future Oncol; 2014 Jun; 10(8):1361-72. PubMed ID: 25052747
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
11. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment.
Spek A; Graser A; Casuscelli J; Szabados B; Rodler S; Marcon J; Stief C; Staehler M
Urol Oncol; 2022 Jan; 40(1):13.e1-13.e8. PubMed ID: 34535355
[TBL] [Abstract][Full Text] [Related]
13. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
14. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
15. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
16. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
Macfarlane R; Heng DY; Xie W; Knox JJ; McDermott DF; Rini BI; Kollmannsberger C; Choueiri TK
Cancer; 2012 Jan; 118(2):365-70. PubMed ID: 21717427
[TBL] [Abstract][Full Text] [Related]
17. Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression.
Scialpi M; Di Maggio A; Midiri M; Loperfido A; Angelelli G; Rotondo A
AJR Am J Roentgenol; 2000 Sep; 175(3):751-7. PubMed ID: 10954462
[TBL] [Abstract][Full Text] [Related]
18. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
Sweis RF; Medved M; Towey S; Karczmar GS; Oto A; Szmulewitz RZ; O'Donnell PH; Fishkin P; Karrison T; Stadler WM
Clin Genitourin Cancer; 2017 Apr; 15(2):207-212. PubMed ID: 27634566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
